Gibson Dunn has advised Serapha Bio, Inc. Latham & Watkins has advised Boundless Bio, Inc. Serapha Bio, Inc., a privately held biotechnology company, and Boundless Bio,...
Serapha Bio and Boundless Bio Announce Merger and $230 Million Private Placement
Mineralys Therapeutics Announces Royalty Repurchase, $500 Million Debt Facility, and $150 Million Equity Offering
Latham & Watkins LLP has advised Mineralys Therapeutics. Cleary Gottlieb has represented the underwriters, including BofA Securities Inc., Goldman Sachs & Co. LLC, and Evercore Group...
Crystalys Therapeutics Launches With $205 Million Series A Financing to Advance Gout Treatment
Latham & Watkins has advised Crystalys Therapeutics. Wilson Sonsini Goodrich & Rosati has advised Novo Holdings and SR One. Crystalys Therapeutics Inc., a clinical-stage biopharmaceutical company,...
Avidity Biosciences Prices $600 Million Upsized Public Offering of Common Stock
Wilson Sonsini Goodrich & Rosati along with Latham & Walkins have advised Avidity Biosciences. Avidity Biosciences, Inc., a biopharmaceutical company listed on Nasdaq under the symbol...
Avidity Biosciences’ $300 Million Common Stock Offering
Latham & Watkins advised Avidity Biosciences on the deal, and Wilson Sonsini Goodrich & Rosati acted as patent counsel to Avidity. Avidity Biosciences, Inc. (Nasdaq: RNA),...
Avidity Biosciences’ $461 Million Common Stock Offering
Latham & Watkins advised Avidity Biosciences, Inc. on the offering, and Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Cooley...
Boundless Bio’s $100 Million IPO
Latham & Watkins and Wilson Sonsini Goodrich & Rosati advised Boundless Bio on the offering, and Cooley advised the underwriters. Boundless Bio, Inc. (Nasdaq: BOLD) a clinical...
Iovance Biotherapeutics’ US$211 Million Common Stock Offering
DLA Piper advised Iovance Biotherapeutics, Latham & Watkins advised the underwriters on the transaction. Iovance Biotherapeutics, Inc. (Iovance), a biotechnology company focused on innovating, developing and...
Structure Therapeutics’ US$300 Million Private Placement Equity Financing
Latham & Watkins LLP represents Jefferies LLC and Leerink Partners LLC acting as placement agents in the financing. Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global...
HilleVax’s €100 Million Common Stock Public Offering
Latham & Watkins Advises HilleVax on Pricing of Public Offering of Common Stock. HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Crinetics Pharmaceuticals’ $350 Million Public Offering of Common Stock
Latham & Watkins advised Crinetics, and Cooley advised the underwriters on the offering. Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced the pricing of an upsized underwritten public...
Iovance Biotherapeutics’ $150 Million Common Stock Public Offering
DLA Piper advised Iovance, and Latham & Watkins advised the underwriters. Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) announced the pricing of an underwritten public offering of 20,000,000 shares...